Placeholder Banner

BIO Asia Conference in Tokyo Cancelled Amid COVID-19 Outbreak

Attendees’ health and safety “utmost priority”

February 21, 2020
Media Contact
Theresa Brady
202.962.9235

Washington, DC – February 21, 2020 - The Biotechnology Innovation Organization (BIO) announced today, it is canceling the annual BIO Asia conference in Tokyo scheduled for March 10-11. The decision was based on the global impact of COVID-19 and Japanese government recommendations.

“Our attendees’ health and safety are our utmost priority,” said Jim Greenwood, BIO President & CEO. “We offer our support and sympathy to all of those who’ve been impacted by the virus around the world.”

Since the coronavirus was first detected in December of last year, brilliant scientists and dedicated researchers across both the public and private sectors have stepped in to begin developing vaccines and antiviral therapies to contain this quickly spreading illness.

“The truth is, the coronavirus is no match for science and the resilient scientific ecosystem of innovators working tirelessly to combat this emerging public health threat,” Greenwood added. “Stakeholders from across the industry are providing resources and capabilities to identify scientific solutions and medical treatments to protect individuals across the globe. We will win this fight, and we look forward to continuing to build a strong biotech ecosystem across Asia and hosting this important event again in the future.”

BIO will return to Japan on March 9-10, 2021 for the next BIO Asia conference in Tokyo. The conference is an exclusive licensing forum that attracts hundreds of delegates eager to explore cross-border licensing deals, research collaborations, and business development investments with Asia’s most innovative biopharma companies.
More information is available on BIO’s website

Learn more about how the biopharmaceutical industry is responding to the coronavirus outbreak.

 

Discover More
The Biotechnology Innovation Organization (BIO) is pleased to announce the election of its new Executive Committee directors for the 2022-2023 term. BIO’s Board elections took place Monday, June 13 during the 2022 BIO International Convention…
The third annual report that examines diversity, equity, and inclusion (DEI) in the biotechnology industry launched today at the 2022 BIO International Convention. The report, “Measuring Diversity in the Biotech Industry: Tracking Progress in Small…
The licensing of university and nonprofit research has made a significant contribution to US gross domestic product (GDP), industrial gross output, and jobs over the last 25 years and underscores the importance of basic and applied research to the…